1
|
Forné C, Subirana I, Blanch J, Ferrieres J, Azevedo A, Meisinger C, Farmakis D, Tavazzi L, Davoli M, Ramos R, Brosa M, Marrugat J, Dégano IR. A cost-utility analysis of increasing percutaneous coronary intervention use in elderly patients with acute coronary syndromes in six European countries. Eur J Prev Cardiol 2020; 28:408-417. [PMID: 33966078 DOI: 10.1177/2047487320942644] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/17/2020] [Accepted: 06/25/2020] [Indexed: 01/08/2023]
Abstract
AIMS Percutaneous coronary intervention reduces mortality in acute coronary syndrome patients but the cost-utility of increasing its use in elderly acute coronary syndrome patients is unknown. METHODS We assessed the efficiency of increased percutaneous coronary intervention use compared to current practice in patients aged ≥75 years admitted for acute coronary syndrome in France, Germany, Greece, Italy, Portugal and Spain with a semi-Markov state transition model. In-hospital mortality reduction estimates by percutaneous coronary intervention use and costs were derived from the EUROpean Treatment & Reduction of Acute Coronary Syndromes cost analysis EU project (n = 28,600). Risk of recurrence and out-of-hospital all-cause mortality were obtained from the Information System for the Development of Research in Primary Care (SIDIAP) database from North-Eastern Spain (n = 55,564). In-hospital mortality was modelled using stratified propensity score analysis. The 8-year acute coronary syndrome recurrence risk and out-of-hospital mortality were estimated with a multistate survival model. The scenarios analysed were to increase percutaneous coronary intervention use among patients with the highest, moderate and lowest probability of receiving percutaneous coronary intervention based on the propensity score analysis. RESULTS France, Greece and Portugal showed similar total costs/1000 individuals (7.29-11.05 m €); while in Germany, Italy and Spain, costs were higher (13.53-22.57 m €). Incremental cost-utility ratios of providing percutaneous coronary intervention to all patients ranged from 2262.8 €/quality adjusted life year gained for German males to 6324.3 €/quality adjusted life year gained for Italian females. Increasing percutaneous coronary intervention use was cost-effective at a willingness-to-pay threshold of 10,000 €/quality adjusted life year gained for all scenarios in the six countries, in males and females. CONCLUSION Compared to current clinical practice, broadening percutaneous coronary intervention use in elderly acute coronary syndrome patients would be cost-effective across different healthcare systems in Europe, regardless of the selected strategy.
Collapse
Affiliation(s)
- C Forné
- Department of Basic Medical Sciences, University of Lleida, Spain
| | - I Subirana
- REGICOR Study Group, IMIM (Hospital del Mar Medical Research Institute), Spain.,CIBER Epidemiology and Public Health, Instituto de Salud Carlos III (ISCIII), Spain
| | - J Blanch
- Vascular Health Research Group (ISV-Girona), Jordi Gol Institute for Primary Care Research (IDIAPJGol), Spain
| | - J Ferrieres
- Department of Cardiology, Toulouse University School of Medicine, France
| | - A Azevedo
- Department of Clinical Epidemiology, Predictive Medicine and Public Health, University of Porto Medical School, Portugal
| | - C Meisinger
- MONICA/KORA Myocardial Infarction Registry, University Hospital of Augsburg, Germany.,Helmholtz Zentrum München, German Research Center for Environmental Health, Germany
| | - D Farmakis
- University of Cyprus Medical School, Cyprus.,Second Department of Cardiology, University of Athens Medical School, Greece
| | - L Tavazzi
- Maria Cecilia Hospital, GVM Care and Research, Italy
| | - M Davoli
- Department of Epidemiology, Lazio Regional Health Service, Italy
| | - R Ramos
- Vascular Health Research Group (ISV-Girona), Jordi Gol Institute for Primary Care Research (IDIAPJGol), Spain.,Catalan Institute of Health, Spain.,Department of Medical Sciences, University of Girona, Spain.,Girona Biomedical Research Institute (IdIBGi), Spain
| | - M Brosa
- Oblikue Consulting SL, Spain
| | - J Marrugat
- REGICOR Study Group, IMIM (Hospital del Mar Medical Research Institute), Spain.,Centro de Investigación Biomédica en Red (CIBER) of Cardiovascular Diseases, ISCIII, Spain
| | - I R Dégano
- REGICOR Study Group, IMIM (Hospital del Mar Medical Research Institute), Spain.,Centro de Investigación Biomédica en Red (CIBER) of Cardiovascular Diseases, ISCIII, Spain.,Faculty of Medicine, University of Vic-Central University of Catalonia (UVic-UCC), Spain
| | | |
Collapse
|
2
|
Dégano IR, Subirana I, Bongard V, Pereira M, Meisinger C, Quinones P, Mastrogiovani L, Jori MC, Lekakis J, Notarangelo I, Sciatella P, Mataloni F, Prosperini G, Davoli M, Grau M, Sala M, Marrugat J. Modelling coronary artery disease incidence in Europe based on population risk factor prevalence. Eur J Public Health 2015. [DOI: 10.1093/eurpub/ckv169.042] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
3
|
Vilalta M, Dégano IR, Bagó J, Aguilar E, Gambhir SS, Rubio N, Blanco J. Human adipose tissue-derived mesenchymal stromal cells as vehicles for tumor bystander effect: a model based on bioluminescence imaging. Gene Ther 2008; 16:547-57. [PMID: 19092860 DOI: 10.1038/gt.2008.176] [Citation(s) in RCA: 35] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/14/2023]
Abstract
Human adipose tissue mesenchymal stromal cells (AMSCs) share common traits, including similar differentiation potential and cell surface markers, with their bone marrow counterparts. Owing to their general availability, higher abundance and ease of isolation AMSCs may be convenient autologous delivery vehicles for localized tumor therapy. We demonstrate a model for tumor therapy development based on the use of AMSCs expressing renilla luciferase and thymidine kinase, as cellular vehicles for ganciclovir-mediated bystander killing of firefly luciferase expressing tumors, and noninvasive bioluminescence imaging to continuously monitor both, tumor cells and AMSCs. We show that the therapy delivering AMSCs survive long time within tumors, optimize the ratio of AMSCs to tumor cells for therapy, and asses the therapeutic effect in real time. Treatment of mice bearing prostate tumors plus therapeutic AMSCs with the prodrug ganciclovir induced bystander killing effect, reducing the number of tumor cells to 1.5 % that of control tumors. Thus, AMSCs could be useful vehicles to deliver localized therapy, with potential for clinical application in inoperable tumors and surgical borders after tumor resection. This approach, useful to evaluate efficiency of therapeutic models, should facilitate the selection of cell types, dosages, therapeutic agents and treatment protocols for cell-based therapies of specific tumors.
Collapse
Affiliation(s)
- M Vilalta
- Cardiovascular Research Center (CSIC-ICCC), CIBER-BBN, Barcelona, Spain
| | | | | | | | | | | | | |
Collapse
|